The long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa...
Read moreThe advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...
Read moreThe population, intervention, comparator, and outcomes (PICO) element of the upcoming EU Joint Clini...
Read moreAUTHORS: Julia Tokarska, Ella Odams, Richard Sloggett, Graham Foxon OBJECTIVES To evaluate if ...
Read moreEU HTA Regulation goes live: A new era for HTA begins The much-awaited implementation of the r...
Read moreThe National Healthcare Security Administration (NHSA) of China completed its annual review of the N...
Read moreWe examine how real-world evidence strategies help address uncertainties in rare disease treatments ...
Read moreAchieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...
Read moreIntroduction What is the secret to a successful drug launch? One crucial factor is establishing a cr...
Read moreOur latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...
Read more